The estimated Net Worth of Mark K Bennett is at least 521$ dollars as of 29 December 2015. Mark Bennett owns over 10,413 units of Calithera Biosciences Inc stock worth over 521$ and over the last 10 years Mark sold CALA stock worth over 0$.
Mark has made over 3 trades of the Calithera Biosciences Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Mark exercised 10,413 units of CALA stock worth 16,661$ on 29 December 2015.
The largest trade Mark's ever made was exercising 18,365 units of Calithera Biosciences Inc stock on 9 July 2015 worth over 28,098$. On average, Mark trades about 5,599 units every 25 days since 2015. As of 29 December 2015 Mark still owns at least 10,413 units of Calithera Biosciences Inc stock.
You can see the complete history of Mark Bennett stock trades at the bottom of the page.
Mark's mailing address filed with the SEC is C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD. #200, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at Calithera Biosciences Inc have traded over 23,150,153$ worth of Calithera Biosciences Inc stock and bought 7,859,025 units worth 49,155,939$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Capital Partners Gp, L.L.C....、Deepika Pakianathan. On average, Calithera Biosciences Inc executives and independent directors trade stock every 43 days with the average trade being worth of 8,053$. The most recent stock trade was executed by Deepika Pakianathan on 27 January 2023, trading 121,333 units of CALA stock currently worth 47,320$.
calithera is focused on discovering and developing first-in-class small molecule drugs that slow tumor growth through controlling key metabolic pathways in the tumor and immune cells. tumor metabolism and tumor immunology are promising new interrelated fields for cancer drug discovery. recent clinical successes have demonstrated the potential to slow abnormal cell growth and create fundamentally new therapies for cancer patients. our investigational onco-metabolism medicines take advantage of the different metabolic requirements of tumor cells and cancer-fighting immune cells. calithera’s discovery and development efforts are focused on solid tumors for which new treatments are urgently needed. we are currently developing our lead candidate in phase 2 trials in patients with renal cell carcinoma, triple negative breast cancer. targeting cancer, differently. our onco-metabolism approach brings an enhanced perspective to cancer.
Calithera Biosciences Inc executives and other stock owners filed with the SEC include: